On April 23, 2020 Spago Nanomedical AB (publ) reported that it has been told that the Japanese patent authority intends to approve the company’s application for product protection for Tumorad (Press release, Spago Nanomedical, APR 23, 2020, View Source [SID1234556538]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The patent applies to the material and is therefore central to the Tumorad project. In addition, Japan is a potentially large market for radionuclide therapies, which is why the patent is important. This shows the height of our innovation and strengthens the project’s commercial conditions, "says CEO Mats Hansen.

The patent entitled "Nanostructures and applications thereof" (application number 2017-501494) is valid until 2035.

The approval means that Spago Nanomedical has product protection for Tumorad in the largest markets for radionuclide therapies. Tumorad already has patent protection in several strategically important regions, including the US and the EU.

Tumorad is being developed as a new type of radionuclide therapy based on Spago Nanomedical’s materials and a therapeutic radioactive isotope for tumor-selective radiation therapy of cancer.

Access to new therapies is a key to effective treatment of many cancers. Tumorad has the potential to treat aggressive and widespread tumors, alone or in synergy with other types of therapies. An extensive program is currently being implemented to document proof of concept for preclinical safety studies and clinical trials.